Investment Rating - The report initiates coverage with a "Buy" rating for the company [2][7]. Core Views - The company is positioned as a ride-hailing platform incubated by Geely Group, focusing on building a new energy vehicle sharing ecosystem. It has achieved rapid business expansion and is on the verge of turning profitable [6][17]. - The ride-hailing industry in China is experiencing high growth, with the company holding the second-largest market share and benefiting from a strong consumer base in first- and second-tier cities [6][51]. - The company is implementing a customized vehicle strategy, which enhances service quality and optimizes cost control, contributing to a clearer path to profitability [6][67]. Financial Data and Profit Forecast - Revenue is projected to grow significantly from 10,668 million RMB in 2023 to 29,931 million RMB in 2027, with a compound annual growth rate (CAGR) of 39.8% from 2023 to 2025 [5][28]. - The net profit attributable to ordinary shareholders is expected to improve from -1,916 million RMB in 2023 to 727 million RMB in 2027, indicating a turnaround in profitability [5][7]. - The company’s gross profit margin is anticipated to increase from 5.8% in 2023 to 15.3% in 2027, reflecting improved operational efficiency [5][34]. Industry Overview - The shared mobility market in China is projected to grow at a compound annual growth rate of 17% from 2025 to 2029, with significant potential for market expansion [6][42]. - The Robotaxi segment is entering a phase of commercialization, with substantial market opportunities anticipated as technology advances [6][58]. Customized Vehicle Strategy - The company operates the largest customized ride-hailing fleet in the country, with a focus on cost-effective vehicle models that enhance user experience and operational efficiency [6][67]. - The total cost of ownership (TCO) for the company's customized vehicles is significantly lower than that of typical electric vehicles, providing a competitive edge [6][72]. Robotaxi Development - The company plans to launch the "Caocao Zhixing" platform in 2025, with initial Robotaxi services already piloted in Suzhou and Hangzhou, indicating a strong commitment to integrating autonomous driving technology [6][63]. - The long-term profit potential of the Robotaxi business is substantial, with estimates suggesting a gross margin exceeding 40% by 2030 [6][7].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 146 / USD 38, indicating a potential upside of 21% from the current price [3][5][24]. Core Insights - The company's revenue for Q2 2025 reached RMB 356.7 billion, a year-on-year increase of 22.4%, surpassing market expectations by 6.5%. This growth was primarily driven by strong performance in the electronics category, benefiting from national trade-in policies [1][2]. - Service revenue grew by 29.1%, with advertising and logistics revenues increasing by 21.7% and 34.3%, respectively, largely due to the rapid growth of the food delivery business [1][2]. - Despite the strong revenue growth, adjusted net profit fell by 50% year-on-year to RMB 7.39 billion, attributed to a significant increase in marketing expenses, which rose by 128% to RMB 27 billion [2][3]. Summary by Sections Revenue Performance - Q2 2025 revenue was RMB 356.7 billion, up 22.4% year-on-year, with product revenue increasing by 20.7% and service revenue by 29.1% [1][2]. - The core category of electronics saw a 23.4% increase, driven by trade-in policies, while daily necessities grew by 16.4% [1]. Profitability Analysis - Gross margin for Q2 was 15.9%, a slight increase of 0.1 percentage points year-on-year. However, adjusted net profit dropped by 50% to RMB 7.39 billion, with an adjusted net profit margin of 2.1% compared to 5.0% in the previous year [2][3]. - The increase in sales expenses, particularly due to food delivery subsidies, led to a sales expense ratio increase from 4.1% to 7.6% [2]. Financial Forecasts - The report slightly raises the FY25E revenue forecast by 3.3%, projecting revenues of RMB 1,324.5 billion for FY25E [3][4]. - Adjusted net profit for FY25E is forecasted at RMB 25.63 billion, with a target P/E ratio of 15.5x [4][3].

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company's performance remains stable, with efficiency improvements in its "Butterfly City" projects. The company is positioned as a leading space technology service provider, leveraging technology to enhance value and manage costs effectively [6] - The company reported a 3.3% year-on-year increase in revenue for the first half of 2025, reaching 18.1 billion yuan, with a core net profit growth of 10.8% [4][6] - The report anticipates that the company's performance will enter a growth phase, despite challenges in the real estate sector [6] Financial Data Summary - For the first half of 2025, the company achieved a net profit of 790 million yuan, a 2.6% increase year-on-year, with a core net profit of 1.32 billion yuan [4] - Revenue projections for the upcoming years are as follows: - 2023: 33.18 billion yuan - 2024: 36.22 billion yuan - 2025E: 38.59 billion yuan - 2026E: 41.36 billion yuan - 2027E: 44.50 billion yuan - The expected net profit for 2025 is 1.53 billion yuan, reflecting a 33% year-on-year growth [5][7]

Investment Rating - The report maintains an "OUTPERFORM" rating for the company, with a target price of HK$88.27, reflecting a potential upside from the current price of HK$68.15 [2][18]. Core Insights - The company achieved a significant turnaround in the first half of 2025, reporting a revenue of Rmb24.25 billion, a 147% year-on-year increase, and a record gross margin of 14.1% [3][13]. - The management has raised its full-year sales guidance for 2025 from 500-600k units to 580-650k units, with a target of reaching 1 million units by 2026 [4][14]. - The company is focusing on rapid expansion in international markets, having established over 600 overseas sales and service outlets, with plans for local assembly in Malaysia and a manufacturing base in Europe [4][15]. Financial Performance - The company reported an adjusted net profit of Rmb330 million in the first half of 2025, marking its first-ever half-year profitability compared to a loss of Rmb2.02 billion in the same period last year [3][13]. - Revenue forecasts for 2025-2027 have been updated to Rmb65.9 billion, Rmb98.5 billion, and Rmb131.8 billion, reflecting increases of 3%, 18%, and 25% respectively [6][17]. - The projected earnings per share (EPS) for 2025-2027 are Rmb0.53, Rmb3.07, and Rmb5.78, indicating a strong growth trajectory [6][17]. Product Development - The upcoming D-series flagship models, including the D16 SUV, are expected to launch in October 2025, targeting the Rmb200k-300k market segment with advanced technology [5][16]. - The company emphasizes a cost-performance strategy, aiming to provide premium features at lower costs, which is expected to enhance its competitive edge in the market [5][16].

Investment Rating - The report maintains a "Buy" rating for Leap Motor (9863.HK) and raises the target price to HKD 83.0, indicating a potential upside of 22% from the current price of HKD 68.15 [2][4]. Core Insights - Leap Motor's sales and net profit guidance for the year exceed expectations, with a target of 580,000 to 650,000 vehicles for 2025. The company anticipates significant growth in both domestic and overseas markets, supported by new model launches and partnerships [8]. - The gross margin is expected to improve, with a forecasted annual gross margin of 14%-15% for the year, driven by increased sales volume and better product mix [8]. - The valuation methodology used is a sum-of-the-parts approach, applying a price-to-sales ratio of 1.6x for 2025 sales, leading to the target price of HKD 83.0 [8]. Financial Performance and Forecast - For Q2 2025, Leap Motor reported revenue of RMB 14.23 billion, a year-on-year increase of 166% and a quarter-on-quarter increase of 42%. The gross margin was 13.6%, up 10.8 percentage points year-on-year [12]. - The company achieved a net profit of RMB 163 million in Q2 2025, marking a return to profitability after a loss in the previous quarter [12]. - Revenue projections for 2023 to 2027 show significant growth, with expected revenues of RMB 16.75 billion in 2023, increasing to RMB 108.44 billion by 2027, reflecting a compound annual growth rate [3][9]. Valuation and Market Position - The current market capitalization of Leap Motor is approximately HKD 91.11 billion, with an average trading volume of HKD 472.2 million over the past three months [4]. - The report highlights that Leap Motor's current price-to-sales ratio is 1.1x, suggesting potential for revaluation as the company continues to grow [8]. - The financial forecasts indicate a steady improvement in profitability, with net losses expected to turn into profits by 2025, projecting a net profit of RMB 634 million [3][9].

Investment Rating - The investment rating for the company is "Maintain Buy" [5] Core Views - The company reported a revenue increase of 1.93% year-on-year for the first half of 2025, achieving a total revenue of RMB 41.835 billion. However, the net profit attributable to shareholders decreased by 1.31% year-on-year to RMB 2.516 billion [1][2][3] - The company continues to distribute dividends, proposing a cash dividend of RMB 0.40 per share, totaling RMB 650 million, which accounts for 25.85% of the net profit for the first half of the year [1][3] Financial Performance Summary - Revenue for 2023 is projected at RMB 75.515 billion, with a year-on-year growth rate of 6.7%. For 2024, revenue is expected to decrease slightly to RMB 74.993 billion, followed by a recovery to RMB 77.589 billion in 2025, representing a growth rate of 3.5% [1][4] - The net profit attributable to shareholders is forecasted to decline to RMB 2.835 billion in 2024, with a subsequent increase to RMB 3.071 billion in 2025, reflecting an 8.3% growth rate [1][4] - The company's return on equity (ROE) is expected to decrease from 11.6% in 2023 to 7.9% in 2024, before gradually improving to 8.9% by 2027 [1][4] - The earnings per share (EPS) is projected to decline from RMB 2.49 in 2023 to RMB 1.74 in 2024, with a recovery to RMB 2.45 by 2027 [1][4] Business Segment Performance - The company’s major business segments include large commercial, health products, and traditional Chinese medicine, with respective revenues of RMB 290 billion, RMB 70.23 billion, and RMB 52.41 billion in the first half of 2025. The health segment showed a growth of 7.42%, while the traditional Chinese medicine segment faced a decline of 15.23% [2][3] - The company is focusing on enhancing its traditional channel coverage for health products and collaborating with major restaurant platforms to boost sales [2] Future Outlook - The company is expected to achieve revenues of RMB 775.89 billion, RMB 813.96 billion, and RMB 847.33 billion from 2025 to 2027, with respective growth rates of 3%, 5%, and 4% [4] - The net profit attributable to shareholders is projected to grow to RMB 30.71 billion, RMB 35.66 billion, and RMB 39.80 billion over the same period, with growth rates of 8%, 16%, and 12% respectively [4]

Investment Rating - The report maintains a "Buy" rating for China Resources Beer [5] Core Views - The company continues to achieve high-end product growth, with a historical high gross margin of 48.9% in H1 2025, driven by the high-end strategy and cost savings in raw material procurement [2][4] - The beer business shows balanced growth across regions, with revenue of 23.16 billion RMB in H1 2025, up 2.6% year-on-year, and sales volume of 6.487 million kiloliters, up 2.2% year-on-year [1][2] - The white liquor business faces industry pressure, with revenue declining by 33.7% year-on-year to 0.781 billion RMB in H1 2025, prompting the company to implement management measures to drive development [2] Summary by Sections Beer Business - Revenue reached 23.16 billion RMB in H1 2025, a 2.6% increase year-on-year - Sales volume was 6.487 million kiloliters, up 2.2% year-on-year - Average selling price increased by 0.4% year-on-year - High-end beer products saw significant growth, with premium and above beer sales increasing by 10% year-on-year [1][2] White Liquor Business - Revenue fell to 0.781 billion RMB in H1 2025, a decrease of 33.7% year-on-year - Major single products contributed nearly 80% of revenue - The company is focusing on management initiatives to drive business development [2] Financial Performance - Gross margin reached a historical high of 48.9%, up 2.0 percentage points year-on-year - The beer business gross margin was 48.3%, up 2.5 percentage points year-on-year - The net profit margin increased by 4.4 percentage points year-on-year to 24.2% [2][4] Future Outlook - The company aims to continue its high-end development strategy, with expectations for net profit growth of 27.7%, 6.9%, and 9.2% for 2025, 2026, and 2027, respectively [2][4]

Investment Rating - The investment rating for the company is "Buy" [5] Core Insights - The company reported a revenue of 9.05 billion yuan for the first half of 2025, representing a year-on-year increase of 11.5%. The adjusted EBITDA was 2.34 billion yuan, up 35.2%, with an adjusted EBITDA margin of 25.9%, an increase of 4.5 percentage points year-on-year [2][5] - The core online travel platform business is experiencing rapid growth, with significant contributions from hotel management, which has over 2,700 operating hotels and a pipeline of 1,500 hotels as of Q2 2025. However, the vacation business faced a decline of 8.0% year-on-year due to safety issues in Southeast Asia [2][3] - The user base continues to expand, with annual paying users growing by 10.2% to 252 million, and 69.0% of new paying users coming from non-first-tier cities [3] - The company aims to deepen its core online travel platform business, enhance its international market presence, and strengthen its hotel management business, which is expected to become a second growth curve for the company [3] Financial Projections - The company is projected to achieve net profits of 2.60 billion yuan, 3.24 billion yuan, and 3.90 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 31.9%, 24.3%, and 20.7% [3][4] - Revenue is expected to grow from 11.90 billion yuan in 2023 to 26.38 billion yuan by 2027, with a compound annual growth rate of approximately 14% [4][9] - The earnings per share (EPS) is forecasted to increase from 0.69 yuan in 2023 to 1.67 yuan in 2027, reflecting a positive growth trajectory [4][9]

Investment Rating - The report maintains a "Buy" rating for China Biopharmaceutical (1177.HK) and raises the target price to HKD 9.1, indicating a potential upside of 15% from the current price of HKD 7.91 [5][6]. Core Insights - In 1H25, the adjusted net profit significantly exceeded expectations, primarily benefiting from a doubling of dividend income from Sinovac. The total revenue for 1H25 was approximately RMB 17.57 billion, reflecting a year-on-year increase of 10.7% and a quarter-on-quarter increase of 35.3% [2][3]. - The company reiterated its guidance for double-digit revenue and adjusted net profit growth for the full year, with the oncology segment showing the fastest growth rate among all segments at 24.9% year-on-year [2][3]. Summary by Sections Financial Performance - For 1H25, the company achieved total revenue of RMB 17.57 billion, with adjusted net profit reaching RMB 3.09 billion, marking a year-on-year increase of 101.1% and a quarter-on-quarter increase of 60.7%. The profit margin improved, with gross margin at 82.5% and adjusted net profit margin at 17.6% [2][3]. - The revenue from innovative products accounted for 44.4% of total revenue, with expectations to increase to 50% by the end of the year. The innovative product revenue reached RMB 7.8 billion, growing 27.2% year-on-year [3][4]. Product Development and Market Expansion - The company is expected to finalize its first overseas licensing deal soon, with several research pipelines anticipated to yield data releases shortly. Key products include TQC3721 and TQB2102, among others, which are expected to show promising results in upcoming clinical trials [4][5]. - The management has indicated that the innovative drugs are projected to achieve over 30% revenue growth, supported by new product launches in 2023-2024 [3][4]. Valuation and Forecast - The adjusted net profit estimates for 2025, 2026, and 2027 have been raised to RMB 5.3 billion, RMB 5.8 billion, and RMB 6.5 billion, respectively, due to the inclusion of sustainable BD income and slight adjustments in innovative drug revenue growth [5][6]. - The DCF valuation model, with a WACC of 8.2% and a perpetual growth rate of 3%, supports the new target price of HKD 9.1 [5][6].

Investment Rating - The report maintains a "BUY" rating for the company, with a target price raised from HK$4.9 to HK$10.2, indicating a potential upside of 29% [6][17]. Core Insights - The company reported a 10.7% year-on-year increase in revenue for the first half of 2025, reaching Rmb17.58 billion, and a 12.3% increase in net profit to Rmb3.39 billion. Adjusted net profit, excluding one-off gains, surged by 101.1% to Rmb3.09 billion, surpassing expectations [6][13]. - The gross margin improved by 0.4 percentage points to 82.5%, while the selling, general, and administrative expenses ratio decreased by 0.2 percentage points to 42.9% [6][13]. - R&D expenses rose by 23.6% to Rmb3.19 billion, with an R&D expense ratio of 18.1%. The company has a cash reserve of approximately Rmb30.5 billion and net cash of Rmb18.5 billion as of June 2025 [6][13]. Summary by Sections Financial Performance - Revenue for the first half of 2025 was Rmb17.58 billion, a 10.7% increase year-on-year. Net profit reached Rmb3.39 billion, up 12.3% year-on-year. Adjusted net profit, excluding one-off items, was Rmb3.09 billion, reflecting a 101.1% increase [6][13]. - The company’s gross margin increased to 82.5%, and the SG&A ratio decreased to 42.9% [6][13]. Innovative Product Growth - Sales of innovative products grew by 27% year-on-year to Rmb7.80 billion, contributing 44% to total revenue in the first half of 2025, up from 39% in the same period last year [7][14]. - The company launched two innovative products in the first half of 2025 and expects to increase the number of innovative products to 21 by 2025 and over 35 by 2027 [8][15]. Acquisition and Pipeline Expansion - The acquisition of LaNova Medicines for a net consideration of US$500 million is expected to enhance the company’s R&D capabilities and expand its innovative pipeline [9][16]. - LaNova Medicines has eight clinical-stage products and over 20 pre-clinical assets, with collaborations with major pharmaceutical companies [9][16].